The TGF-beta
INTRODUCTION
Oocyte competence is a limiting factor for the establishment of pregnancy. Indeed, it is well established that poor oocyte quality is the major cause of infertility for women of advanced reproductive age [1] . Poor oocyte quality is also linked with highly costly embryonic loss and poor reproductive efficiency currently plaguing high producing dairy cows [2] . Moreover, poor oocyte quality is the major factor responsible for the inefficiency of reproductive technologies, such as in vitro embryo production [3] [4] [5] .
Oocyte competence is acquired throughout folliculogenesis and regulated by a combination of genetic, epigenetic, and physiological mechanisms. Of particular note, during this developmental window, the oocyte accumulates maternal factors, including mRNAs, proteins, and energy substrates, which are necessary to foster early embryonic development immediately after fertilization given that early embryos lack transcriptional ability necessary for development until embryonic genome activation (EGA) occurs at the 8-to 16-cell stage in cattle and 2-cell stage in mouse [6, 7] . Hence, multiple oocyte-stored factors (maternal factors) are required for early embryonic development [7, 8] . Such genes, whose deficiency in oocytes results in phenotypes in embryos after fertilization, are classified as maternal-effect genes [7] . To date, most known maternal-effect genes have been identified in mouse because of its utility for ablating gene function via gene targeting. However, limited information is known relative to the identity and the function of important maternal-effect genes that are required for early embryogenesis in domestic animals, including cattle.
To increase understanding of molecular mediators of oocyte quality and maternal regulation of early embryogenesis, we have performed fundamental studies using the bovine model to identify and characterize the functional role of key maternal factors using microarray analysis in conjunction with RNA interference (RNAi) and pharmacological approaches. The bovine model was used as a dual-purpose model relevant to human assisted reproductive technologies (ART) because ovarian physiology and many aspects of embryo development and ART are similar between the two (humans and bovine) single-ovulating species. Initially, microarray analysis was performed to identify differentially expressed RNA transcripts associated with oocyte quality comparing bovine adult cow oocytes (good quality) with prepubertal calf oocytes (poor quality) [9] . Such studies revealed follistatin transcript abundance is positively associated with oocyte quality [9] . Further functional studies revealed that follistatin addition to culture medium during the initial 72 h of embryo culture increased the proportions of embryos cleaving early, development to the blastocyst stage, and trophectoderm (TE) cell numbers in blastocysts [10] . In contrast, small interfering RNA (siRNA)-mediated knockdown of follistatin in bovine embryos results in decreases in blastocyst rates and TE cell numbers [10] . Exogenous follistatin regulation of early cleavage and blastocyst rates was also demonstrated with rhesus monkey embryos [11] . However, the mechanisms responsible for the embryotropic actions of follistatin remain unclear.
Follistatin is best known as a high-affinity activin-binding protein [12] . However, follistatin also can bind and regulate biological activity of several other TGF-b superfamily members, including specific BMPs and inhibins [13, 14] . Activity of TGF-b ligands is mediated predominantly through SMAD signaling [15] . Briefly, upon binding between TGF-b ligand and type II receptor, the type I receptor is recruited and phosphorylated, which in turn, activates SMADs (R-SMADs) by phosphorylation. SMAD2/3 are activated by activin and TGF-b binding to cognate receptors while SMAD1/5/8 are activated by BMPs. Once activated, R-SMADs bind to SMAD4 and then are imported to the nucleus, where they regulate gene transcription. We previously demonstrated that SMAD4 is involved in specific embryotropic actions of follistatin [16] . While SMAD4 is a common SMAD that can bind both SMAD2/3 and SMAD1/5/8, the specific SMADsignaling pathways potentially linked to the embryotropic actions of follistatin are unclear.
In the present studies, we determined the functional role of SMAD2/3 in bovine early embryonic development and the relationship between SMAD2/3 signaling and the embryotropic actions of follistatin. Results show SMAD2 and SMAD3 are both present in bovine oocytes and preimplantation embryos with a typical characteristic expression pattern of maternally expressed genes. Inhibition of SMAD2/3 signaling by either siRNA-mediated gene-silencing procedures or pharmacological approaches in zygotes markedly reduced subsequent development to the blastocyst stage. Furthermore, embryotropic actions of follistatin on blastocyst development, but not early cleavage, are lost when SMAD2/3 signaling is inhibited. Collectively, the results indicate SMAD2/3 signaling is required for bovine early embryogenesis and the positive actions of follistatin on blastocyst development are blocked when SMAD2/3 signaling is ablated.
MATERIALS AND METHODS

Materials
Unless otherwise indicated, the reagents and chemicals were purchased from Sigma-Aldrich.
In Vitro Maturation, In Vitro Fertilization, and In Vitro Embryo Culture
For in vitro maturation (IVM) studies, bovine ovaries were obtained from a local slaughterhouse. After a brief wash, cumulus oocyte complexes (COCs) were aspirated from ovaries with an 18-gage needle connected to a syringe. Those COCs enclosed by at least three layers of cumulus cells were selected for IVM. IVM medium consisted of Medium-199 with Earle salts (base medium), 10% fetal bovine serum (FBS) (Gibco-BRL), 1 lg/ml estradiol-17b, 1 international unit/ml FSH, and 5 international units/ml LH (Sioux Biochemical). Fifty COCs/well were incubated in 4-well plates (Nunc) at 38.58C under 5% CO 2 in air for 22-24 h For in vitro studies (IVF), matured COCs were washed briefly three times with IVF medium [10, 16] . Spermatozoa were purified from frozen-thawed semen with a Percoll gradient and concentration determined using a hemocytometer [10, 16] . Then, sperm was added to IVF medium containing 50 COCs/well at a concentration of 1 3 10 6 /ml. After 16-18 h incubation at 38.58C under 5% CO 2 in air, cumulus cells were removed from COCs by vortexing for 5 min.
For in vitro embryo culture (IVC) studies, zygotes were first cultured in in vitro embryo culture medium that consists of potassium simplex optimization medium (KSOM) (MR-121-D; Millipore) and 0.3% bovine serum albumin (BSA). After 3 days, 8-to 16-cell embryos were collected, washed and incubated in medium consisting of fresh KSOM containing 10% fetal bovine serum and 0.3% BSA until Day 7 (d7).
Expression Profile of SMAD2/3 During Early Embryonic Development
Oocytes and embryos were used for quantitative PCR (qPCR) analysis as described previously [17, 18] . Oocytes/embryos were collected at the following time points: 1) oocytes: germinal vesicle (GV) and MII, 24 h after bovine oocyte maturation; 2) zygotes: 20 h postinsemination (hpi); 3) 2-cell: 33 hpi; 4) 4-cell: 44 hpi; 5) 8-cell: 52 hpi; 6) 16-cell: 72 hpi; 7) and morula and blastocysts at 5 and 7 days postinsemination (n ¼ 10 oocytes/embryos per time point, n ¼ 4 replicates). To determine if SMAD2/3 mRNA in early embryos is of maternal or zygotic origin, zygotes were treated with or without 50 lg/ml aamanitin (RNA polymerase II inhibitor), and 8-cell embryos were collected at 52 hpi (n ¼ 10 embryos/group, n ¼ 4 replicates).
RNAi in Bovine Preimplantation Embryos
Design, synthesis, and microinjection of siRNA were performed according to our previously published studies [10, [19] [20] [21] . All the siRNAs were initially examined to rule out potential nonspecific targets by performing Basic Local Alignment Search Tool analysis. The antisense and sense oligo template sequences for these siRNAs are: SMAD2 siRNA 1-antisense: AAGAGG AGTGCGCTTATATTACCTGTCTC, sense: AATAATATAAGCGCA CTCCTCCCTGTCTC; SMAD2 siRNA 2-antisense: AAATACGATAGATCA GTGGGACCTGTCTC, sense: AATCCCACTGAT CTATCGTAT CCTGTCTC; SMAD3 siRNA 1-antisense: AATATTCCAGAAACCCCACCC CCTGTCTC, sense: AAGGGTGGGGTT TCTGGAATACCTGTCTC; SMAD3 siRNA 2-antisense: AATGCCTCAGTGACAGCGCCACCTGTCTC, sense: AATGGCGCTGTCACTGAGGCAT TCCTGTCTC. Each siRNA was tested individually for efficacy in silencing endogenous SMAD2 or SMAD3 in bovine early embryos. A cocktail of two effective siRNAs/gene (25 lM) was delivered into putative zygotes (collected at 16-18 hpi) by microinjection in a volume of 20 pl. Then, 4-cell embryos were separated and collected at 42-44 hpi for qPCR analysis (n ¼ 10 embryos/pool; n ¼ 3 replicates). Control embryos were either uninjected or injected with a nonspecific universal negative control siRNA (25 lM) (No. 1; Ambion) for the RNAi.
Western blot analysis was also performed to test the efficacy of siRNA in reducing total SMAD2/3 and phosphorylated-SMAD2/3 abundance in early embryos (n ¼ 20-40 embryos/treatment, n ¼ 3 replicates). Effect of SMAD2 knockdown on the percentage of embryos that cleaved early (30 hpi), total cleavage rate (48 hpi), and the proportion of embryos developing to 8-to 16-cell stage (72 hpi) and blastocyst stage (7 days after insemination) were also determined (n ¼ 25-30 per treatment, n ¼ 7 replicates).
For experiments to examine if embryotropic actions of follistatin are SMAD2/3 dependent, two approaches were used. For RNAi approach, uninjected and SMAD2 or SMAD2 and SMAD3 siRNA-injected zygotes were treated with the optimal dose of follistatin (10 ng/ml; control embryos) or increasing concentrations of follistatin (0-100 ng/ml follistatin; SMAD2 or SMAD2 and SMAD3 siRNA-injected embryos) for the first 72 h of embryo culture. Then, they were transferred to fresh medium minus follistatin and cultured until d7 (n ¼ 25-30 embryos per treatment; n ¼ 6 replicates). For pharmacological approaches used to inhibit SMAD2/3 signaling, zygotes were exposed to the optimal dose of follistatin (10 ng/ml; control embryos) or increasing concentrations of follistatin (0-100 ng/ml follistatin) in the presence of SB431542 or SIS3 (nature of inhibitors and concentrations described below) for the first 72 h of embryo culture (n ¼ 25-30 embryos per treatment; n ¼ 7 replicates). Effects of treatments on early cleavage, total cleavage rates, and percent development to 8-to 16-cell and blastocyst stages were monitored as described above.
For the experiment to test the effect of SMAD2 knockdown on selected markers of inner cell mass (ICM) and TE, zygotes were microinjected (16-18 hpi) with SMAD2 siRNA (cocktail) or negative control siRNA species 1 or served as uninjected controls. Embryos were collected on d6 (n ¼ 4 pools of 5 embryos each per group) for qPCR analysis against the ICM marker NANOG and TE cell markers CDX2 and CTGF. Similar qPCR analysis was performed as described above on d7 blastocysts to determine effect of SB431542 treatment (10 lM) on NANOG and CDX2 expression (n ¼ 3 pools of 5 embryos each per treatment).
Western Blot Analysis
Oocytes/embryos (n ¼ 20-40 oocytes/embryos per pool) were collected in 20 ll lysis buffer, that is, RIPA buffer supplemented with protease and phosphatase inhibitor (Roche Applied Science) and stored at À808C until used.
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The samples were then mixed with sample buffer (Laemmli buffer: 0.25 M Tris-chloride, pH 6.8, 15% SDS, 50% glycerol, 25% b-mercaptoethanol, 0.01% bromophenol blue) and separated by gel electrophoresis using 4%-20% precast gels (Bio-Rad). Electrophoresis was performed at 150 V for 70-90 min. The proteins were transferred onto a polyvinylidene difluoride (Millipore) membrane with a tank electrophoretic transfer apparatus (Bio-Rad) at 95 V for 65 min at 48C. Membranes were blocked for 1 h in 5% BSA in 137 mM NaCl, 20 mM Tris, 0.5% Tween-20, pH 7.5, and incubated overnight with the primary antibodies on a rotating shaker at 48C: anti-total SMAD2/3 (1/1000 dilution; Cell Signaling), anti-phospho-SMAD2/3 (1/1000 dilution; Cell Signaling), anti-total SMAD3 (1/1000 dilution; Cell Signaling), anti-phospho-SMAD3 (1/1000 dilution; Cell Signaling), or anti-actin (1/5000 dilution, Millipore). Blots were incubated for 1 h in horseradish peroxidase-conjugated secondary antibody diluted 1:5000 in 137 mM NaCl, 20 mM Tris, 0.5% Tween-20, pH 7.5, with 5% BSA. Protein signals were detected with SuperSignal West Dura Chemiluminescent Substrate (Thermo Scientific); and images were scanned using myECL Imager (Thermo Scientific); and signal intensity was quantified using ImageJ software (http://imagej.nih.gov/ij/). The blots were stripped using stripping buffer (Restore Western Blot Stripping Buffer; Thermo Scientific) for reprobing.
To evaluate the efficacy of two commercial inhibitors SB431542 and SIS3 in blocking phosphorylation of SMAD2/3 and SMAD3, respectively, putative zygotes were cultured in the presence or absence of each inhibitor at two doses (10 and 100 lM) for 24 h. Embryos were collected and subjected to Western blot analysis as described above (n ¼ 40 embryos per treatment, n ¼ 3 replicates).
Quantitative RT-PCR
RNA isolation, cDNA synthesis, and qPCR were performed according to procedures published before [10, 17] . SsoAdvanced Universal SYBR Green Supermix (BioRad) was used for quantification of all the transcripts. The primer sequences used were: SMAD1 and SMAD5 [18] ; SMAD4 [16] ; connective tissue growth factor (CTGF) [22] ; SMAD2 (NM_001046218) forward: TGCCGAGTGCCTAAGTGACA, reverse: GGTGCCAGCCATA
TCTCTGATT; SMAD3 (NM_001205805) forward: GGAGCCGAGTACAGG A G A C A , r e v e r s e : A A A G G T C C A T T C A G G T G C A G ; N A N O G (NM_001025344) forward: AAAGTTACGTGTCCTTGCAAACG, reverse:
GAGGAGGGAAGAGGAGAGACAGT; CDX2 (AM293662) forward: FCGTCTGGAGCTGGAGAAGGA, reverse: CGGCCAGTTCGGCTTTC; RPS18 (NM_001033614) forward: GTGGTGTTGAGGAAAGCAGACA, reverse: TGATCACACGTTCCACCTCATG. Relative mRNA level was calculated using the formula 2 ÀDDCT and was normalized to endogenous control (RPS18).
Statistical Analysis
One-way ANOVA was performed using SAS 9.4 (SAS Institute) for data analysis with all percentage data arc-sin transformed before analysis, but all the data are presented as untransformed. Differences among treatment means were compared using Fisher protected least significant difference test.
RESULTS
Dynamic Expression of SMAD2/3 in Bovine Preimplantation Embryos
As shown in Figure 1 , qPCR analysis revealed that SMAD2 and SMAD3 mRNAs were present in both immature and mature oocytes as well as early bovine embryos produced by IVF. Specifically, SMAD2 (Fig. 1A) and SMAD3 (Fig. 1B ) mRNA abundance were high in bovine oocytes, sustained after IVF, reached peak levels at the 2-cell stage, and dropped markedly from the 16-cell stage onward. Western blot analysis revealed that both the phosphorylated form of SMAD2/3 (pSMAD2/3) and total SMAD2/3 (tSMAD2/3) were maximal in immature and mature bovine oocytes and decreased dramatically after fertilization (Fig. 1C) . However, both pSMAD2/3 and tSMAD2/3 protein levels were very low in morula and blastocysts.
The dynamic expression pattern of SMAD2 and SMAD3 described above suggested that SMAD2 and SMAD3 present in early embryos was likely of maternal origin and may be important for early stages of embryogenesis after fertilization. To determine the origin of the SMAD2 and SMAD3 mRNAs detected prior to the 8-to 16-cell stage, when the major wave of EGA occurs, presumptive zygotes were treated with the RNA polymerase II inhibitor, a-amanitin, and qPCR analysis of SMAD2 and SMAD3 mRNA levels was performed (either total or polyadenylated) in the resulting 8-cell embryos. As shown in Figure 1 , D and F, polyadenylated SMAD2 and SMAD3 mRNA level was not reduced following transcriptional inhibition, but rather was increased by 5-fold after treatment with a-amanitin (P , 0.05). However, total SMAD2 and SMAD3 mRNA abundance was relatively stable after aamanitin treatment (Fig. 1, E and G 
To determine the specific functional role of SMAD2 during early embryogenesis, siRNAs against SMAD2 were designed and two siRNA species that exhibited robust knockdown efficiency were obtained (Supplemental Fig. S1A ; all Supplemental Data are available online at www.biolreprod.org). Then, the cocktail of these two siRNAs was used for the subsequent experiments. As shown in Figure 2A , endogenous SMAD2 mRNA abundance was significantly reduced upon microinjection of siRNA cocktail compared to uninjected or negative control siRNA-injected embryos (P , 0.05). Consistent with this result, Western blot analysis using SMAD2/3 antibodies demonstrated that both total and phosphorylated SMAD2 protein abundance was markedly reduced (91% and 100%, respectively) in SMAD2 siRNA-injected embryos (Fig. 2B) . In additional validation studies, no effect of SMAD2 siRNA injection on the abundance of SMAD3 mRNA (Supplemental Fig. S2A ) or protein (Supplemental Fig. S3C ) was observed.
Analysis of early embryonic development revealed that the proportion of embryos cleaving within 48 hpi (total cleavage) was not changed following SMAD2 siRNA injection compared with both control groups (Fig. 2C) . However, the percentages of embryos developing to the 8-to 16-cell stage (P , 0.05, Fig.  2D ) and blastocyst stage (P , 0.05, Fig. 2E ) were decreased sharply in SMAD2 siRNA-injected embryos compared with controls, indicating a poor developmental competence of SMAD2-deficient embryos.
To examine if embryo quality was influenced by ablating SMAD2, one key developmental event, early lineage specification that occurs in late morula/early blastocysts, was analyzed [23] . Embryos were collected on d6, and qPCR analysis against selected genes, including the ICM-specific gene NANOG and TE-specific genes CDX2 and CTGF, was performed. No difference in the mRNA abundance of NANOG and CDX2 was found between SMAD2 knockdown embryos versus controls (Fig. 3, A and B) . However, CTGF mRNA abundance in SMAD2-deficient embryos was reduced compared to controls (P , 0.05, Fig. 3C ), suggesting SMAD2 knockdown affects expression of specific TE-expressed genes in bovine embryos.
siRNA-Mediated Ablation of Both SMAD2 and SMAD3 Suppresses Bovine Early Embryonic Development
The above results suggest SMAD2 ablation affected multiple indices of bovine early embryonic development. Given expression patterns of SMAD2 and SMAD3 detected are quite similar (Fig. 1) and both likely contribute to early ROLE OF SMAD2/3 IN BOVINE EARLY EMBRYOS embryogenesis, we also tested siRNAs to ablate SMAD3 in early embryos with the goal to test the effects of combined SMAD2 and SMAD3 ablation. Two effective siRNAs against SMAD3 were identified (Supplemental Fig. S1B ). Both SMAD3 mRNA and protein abundance were reduced (44% and 85% for tSMAD3 and pSMAD3, respectively) after microinjection of the SMAD3 siRNA cocktail into presumptive zygotes (Supplemental Fig. S3, A and B ) and no effect of SMAD3 siRNA on SMAD2 mRNA abundance was observed (Supplemental Fig. S2B ). To deplete both SMAD2 and SMAD3 mRNA, siRNA cocktail including siRNAs targeting SMAD2 and SMAD3 were injected together into bovine , and blastocyst (BL) stages were collected and subjected to qPCR analysis (n ¼ 4 pools of 10 oocytes/embryos per pool) for SMAD2 (A) and SMAD3 (B) or Western blot assay for SMAD2/3 (C, n ¼ 3 pools of 20-40 oocytes/embryos per pool). D-G) Putative zygotes were treated with or without a-amanitin (50 lg/ml), a RNA polymerase II inhibitor, to determine if SMAD2 and SMAD3 transcripts in early embryos are maternal or zygotic in origin. At 52 hpi, embryos were collected (n ¼ 4 pools of 10 embryos each per group) for qPCR analysis of SMAD2 (D, E) and SMAD3 (F, G) mRNA. The RNA was primed with 1 ll of 100 lM oligo dT (D, F) for the detection of polyadenylated (Aþ) transcripts or 1 ll of 20 lM random hexamers (E, G) for the detection of total transcripts. Data were normalized to endogenous control (RPS18) and are shown as mean 6 SEM. Different superscripts across time points indicate significant differences (P , 0.05).
ZHANG ET AL.
zygotes. Quantitative PCR analysis indicated that siRNA microinjection successfully reduced both endogenous SMAD2 and SMAD3 mRNAs (P , 0.05, Supplemental Fig. S3, C and  D) . Western blot analysis showed that both active and total SMAD2/3 proteins were reduced by 58% and 48%, respectively, in ;8-cell stage embryos following coinjection of SMAD2 and SMAD3 siRNAs at the zygote stage (Supplemental Fig. S3E) .
The results of SMAD2 and SMAD3 siRNA microinjection revealed that the proportions of embryos cleaving within either FIG. 2. SMAD2 is required for bovine early embryonic development. In vitro produced zygotes were microinjected (16-18 hpi) with ;20 pl of SMAD2 siRNA cocktail (25 lM: species 1 þ 2) or negative control siRNA species 1 (25 lM). The 4-cell stage embryos were collected at 42-44 hpi (n ¼ 3 pools of 10 embryos each per treatment) for qPCR analysis of SMAD2 mRNA (A). The 8-cell stage embryos were harvested at 52 hpi and subjected to Western blot assay (B, n ¼ 3 pools of 30 embryos each per treatment). Data were normalized to endogenous control (RPS18) and are shown as mean 6 SEM. Presumptive zygotes were cultured in KSOM medium supplemented with 0.3% BSA (25-30 presumptive zygotes per group, 7 replicates). The 8-to 16-cell stage embryos were separated 72 hpi and cultured in fresh KSOM medium supplemented with 0.3% BSA and 10% FBS until d7. In vitro development for following endpoints was monitored: total cleavage rate (determined 48 hpi) (C), proportion of embryos developing to the 8-to 16-cell stage (72 hpi) (D), and proportion of embryos developing to the blastocyst stage (d7) (E). All the percentages were calculated relative to the number of zygotes cultured for each treatment and are expressed as mean 6 SEM. Different superscripts indicate significant differences (P , 0.05).
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30 h (early cleaving) or 48 h (total cleavage) were not affected for embryos injected with both SMAD2 and SMAD3 siRNAs compared to controls (Fig. 4, A and B) . However, the percentages of embryos developing to the 8-to 16-cell and blastocyst stages were both decreased in SMAD2/3-deficient embryos (P , 0.05, Fig. 4, C and D) . The results further support a requirement of SMAD2/3 signaling for early embryonic development in cattle.
Impact of Ablation of SMAD2/3 Signaling on Specific Embryotropic Actions of Follistatin
To determine whether embryotropic actions of follistatin were altered when SMAD2/3 signaling was inhibited, the effects of exogenous follistatin treatment on SMAD2 and SMAD3 siRNA-injected embryos were determined. Follistatin treatment (10 ng/ml) increased the early cleavage rate similarly in SMAD2 and SMAD3 siRNA-injected embryos (P , 0.05, Fig. 4A ) but failed to increase the percentages of embryos developing to the 8-to 16-cell and blastocyst stages (Fig. 4, C  and D, respectively) . Similar results were observed in FIG. 3 . Effect of SMAD2 knockdown on selected molecular markers of ICM and TE. Presumptive zygotes were microinjected (16-18 hpi) with SMAD2 siRNA (cocktail) or negative control siRNA species 1 or served as uninjected controls. Late morula were collected on d6 (n ¼ 4 pools of 5 embryos each per group) for qPCR analysis against the ICM marker NANOG (A) and TE cell markers CDX2 (B) and CTGF (C). Data were normalized to endogenous control (RPS18) and are shown as mean 6 SEM. Different superscripts indicate significant differences (P , 0.05).
follistatin-treated embryos injected with SMAD2 siRNA alone (Supplemental Fig. S4 ). The results suggest that specific stimulatory actions of follistatin on development to 8-to 16-cell and blastocyst stages were lost when SMAD2/3 signaling was inhibited.
The results also suggest that SMAD2 and SMAD3 siRNA injection did not affect the proportion of embryos that cleave early, but the short time window following SMAD2 and SMAD3 siRNA injection into zygotes until early cleavage may not be long enough to allow sufficient inhibition of this signaling pathway. Hence, pharmacological approaches that inhibit SMAD2/3 (SB431542 treatment) and SMAD3 (SIS3 treatment) were used to further investigate the contribution of this signaling pathway to early cleavage and stimulatory effects of follistatin. Putative zygotes were treated with diluent (i.e., dimethyl sulfoxide) or two doses of SB431542 and SIS3 in preliminary dose-response studies and changes in SMAD2/3 phosphorylation and early embryonic development was monitored. Western blot analysis showed that phosphorylation of SMAD2/3 was inhibited by 47% in the presence of 10 lM FIG. 4 . Effect of exogenous follistatin treatment on in vitro development of SMAD2 and SMAD3-ablated embryos. In vitro produced zygotes were microinjected (16-18 hpi) with ;20 pl of SMAD2 and SMAD3 siRNA cocktail. Uninjected and siRNA injected zygotes were cultured with or without 1, 10, or 100 ng/ml follistatin (n ¼ 25-30 presumptive zygotes per treatment; n ¼ 6 replicates; 10 ng/ml dose only for uninjected embryos). The 8-to 16-cell stage embryos were then separated and cultured in fresh medium without follistatin until d7. A) Percentage of embryos that cleaved within 30 hpi (early cleaving). B) Total cleavage rate (determined 48 hpi). C) Proportion of embryos developing to the 8-to 16-cell stage (72 hpi). D) Proportion of embryos developing to the blastocyst stage (d7). All the percentages were determined relative to the number of zygotes cultured for each treatment and are expressed as mean 6 SEM. Different superscripts indicate significant differences (P , 0.05).
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dose of SB-431542 and phosphorylation of SMAD3 was inhibited by 31% in the presence of 10 lM dose of SIS3, indicating both inhibitors (at the lower dose tested) were effective in reducing target SMAD phosphorylation in bovine early embryos (Fig. 5, A and B) . Developmental results (using 10 lM concentration of either inhibitor) indicated early cleavage and total cleavage were not affected for embryos treated with either SB431542 (Fig. 5, C and D) or SIS3 (Fig. 5 , E and F) compared with controls, and no effects of SB431542 treatment on NANOG and CDX2 mRNA abundance in d7 blastocyst were observed (Supplemental Fig. S5, A and B) . For inhibitor-treated embryos treated with follistatin, stimulatory effects of follistatin treatment on early cleavage were still observed (Fig. 5, C and E) . However, the proportions of embryos developing to the 8-to 16-cell and blastocyst stages were reduced significantly in the presence of either SB431542 (P , 0.05, Supplemental Fig. S6, A and B) or SIS3 (P , 0.05, Supplemental Fig. S6 , C and D) relative to controls, and inhibitory effects on development were not rescued in response to follistatin treatment. The results support a specific requirement of SMAD2 and SMAD3 for bovine early embryonic development and link to specific embryotropic actions of follistatin.
DISCUSSION
The functional role of genes of maternal origin in the regulation of early embryogenesis remains poorly understood in most mammalian species, including cattle. Using two independent approaches, we demonstrated that SMAD2 and SMAD3 are required for bovine early embryonic development and specific embryotropic actions of follistatin during early development are lost when SMAD2/3 signaling is ablated. Collectively, our results indicate that TGF-b superfamily cognate-signaling pathway components, SMAD2/3/4, are key genes of maternal origin whose products play an essential role in early embryonic development. Furthermore, the results also indicate the stimulatory actions of follistatin on development to the 8-to 16-cell and blastocyst stages, but not early cleavage, are dependent on functional SMAD2/3 and SMAD4.
Multiple key components, including ligands and receptors, of the TGF-b superfamily signaling pathway are expressed in oocytes and preimplantation embryos with species-specific patterns in mouse, human, and cattle [16, 18, [24] [25] [26] [27] . TGF-b superfamily members (e.g., BMP15 and GDF9) or associated growth factor-binding proteins (e.g., follistatin) have been shown to regulate oocyte maturation and (or) early embryogenesis in cattle [10, 28, 29] . However, little is known about the role of specific SMAD-signaling pathways in the regulation of early embryogenesis. The results presented here demonstrate that SMAD2 and SMAD3 are both expressed in bovine oocytes and embryos throughout the early development with a maternal-origin expression pattern. Furthermore, the results of embryo culture in the presence of a-amanitin (Fig. 1, D and  F) suggest that the decline in SMAD2 and SMAD3 mRNA, which also was observed previously for SMAD4 [16] , during maternal-embryonic transition is itself transcription dependent. Although further investigation will be required, this regulation is possibly mediated by transcript deadenylation because adenylation and deadenylation of mRNAs are prominent mechanisms involved in the regulation of mRNA levels during the maternal-embryonic transition [30, 31] .
Protein analysis indicates that total SMAD2/3 and phosphorylated SMAD2/3 abundance is low in morulae and blastocysts relative to premorulae stages, and highest SMAD2/3 protein levels was observed in both immature and mature oocytes, suggesting an important role of SMAD2/3 in oocyte maturation, which warrants further investigation. The dramatic decrease in SMAD2/3 protein abundance is in contrast with the slight change in SMAD2/3 mRNA level between pre-and postfertilization, which potentially suggests dynamic posttranslational regulation of SMAD2/3 protein. Dynamic posttranscriptional and posttranslational regulatory mechanisms are characteristic of the maternal-to-embryonic transition and critical to development [30] . Indeed, regulation of SMAD2/3 via ubiquitination is implicated in the degradation of SMAD2/3 and regulation of the TGF-b signaling pathway [32] [33] [34] . Collectively, these results, together with our previous reports about the expression of SMAD4 [16] and SMAD1/5 [18] in preimplantation embryos, suggest SMAD-signaling pathways are active and may play an important role during bovine early embryonic development.
The functional roles of TGF-b-SMAD-signaling pathways in preimplantation embryos remain largely unknown, especially in large animals, including cattle. SMAD2-null mice exhibit embryonic lethality between Embryonic Days 6.5 and 8.5, suggesting a functional requirement for postimplantation development [35, 36] . In contrast, SMAD3 knockout does not affect pregnancy success, but SMAD3-null mice develop inflammatory diseases, indicating that it is required for the anti-inflammatory response [37] . In the present study, microinjection of siRNAs efficiently reduced endogenous SMAD2 and/or SMAD3 mRNA and protein. The percentage of embryos cleaving was not affected, but the proportion of embryos developing to the 8-to 16-cell and blastocyst stages decreased in SMAD2-deficient or SMAD2 and SMAD3 coknockdown groups relative to both uninjected and negative control siRNA-injected controls. Alternatively, these developmental defects were phenocopied when embryos were treated with an inhibitor of the SMAD2/3 signaling pathway or a specific inhibitor of SMAD3. Similar results were obtained previously with embryos depleted of SMAD4, the common SMAD linked to signaling via both SMAD2/3 and SMAD1/5. Hence, future studies are warranted to determine the functional role of SMAD1/5 in bovine embryonic development.
The first lineage specification/cell differentiation event is initiated in the morula and completed in the blastocyst, where the outside cells have differentiated in TE cells and inside cells to ICM cells. TE cells contribute to the majority of placental tissue, and ICM cells develop into the embryo proper. Previous work showing colocalization of SMAD2/3 and YAP in mouse embryos suggest the SMAD2/3-signaling pathway may be involved in the process of lineage specification (ICM and TE) [25] . Recent data in mouse epiblast stem cells indicate SMAD2 is required for maintenance of the pluripotent state [38] . The results of the present studies indicated mRNA expression of key molecular markers of TE and ICM (CDX2 and NANOG) was not affected by SMAD2 siRNA injection or pharmacological inhibition of SMAD2/3 signaling. However, expression of mRNA for the TE-specific gene CTGF was reduced significantly in SMAD2-deficient embryos compared to controls. CTGF is a cysteine-rich protein belonging to the CCN protein family [39] . CTGF is involved in a variety of biological activities, including ovarian follicle development [40] . It has been shown recently that CTGF is specifically localized in TE cells in bovine blastocysts [22] . Interestingly, the TGF-b signaling pathway is involved in regulation of the synthesis and secretion of CTGF [41] . The results demonstrate that SMAD2 ablation affects the expression of the TGF-b responsive gene CTGF in early embryos. Further studies would be necessary to define the functional role of CTGF in TE development in cattle ZHANG ET AL. and delineate the specific TGF-b superfamily ligands linked to SMAD2/3 regulation of CTGF expression.
We have previously demonstrated specific embryotropic actions of follistatin during bovine early embryonic development [10] . Follistatin is a known binding protein for selected members of the TGF-b superfamily and is hypothesized to take part in regulation of biological functions via ligand binding in the extracellular milieu and indirect regulation of stimulation of SMAD-signaling pathways. The present studies examined the effects of treatment with exogenous follistatin on bovine preimplantation embryos injected with SMAD2/3 siRNA or exposed to pharmacological inhibitors of SMAD2/3 signaling (SIS3 or SB431542). The results showed that stimulatory actions of follistatin on bovine early embryogenesis were blocked by either ablating SMAD2/3 mRNA or treatment with SB431542 or SIS3 in terms of the percentages of embryos developing to the 8-to 16-cell and blastocyst stages. However, the stimulatory effects of follistatin on early cleavage rate were not affected for embryos treated with siRNA or pharmacological inhibitors of SMAD2/3 signaling. Previous studies also demonstrated that stimulatory effects of follistatin treatment on early cleavage are not impeded by siRNA-mediated SMAD4 knockdown [16] . Collectively, the results suggest the embryotropic effects of follistatin that accelerate the first cell cycle are SMAD2/3 and SMAD4 independent. A multitude of SMAD-independent signaling pathways linked to biological activity of TGF-b superfamily ligands have been reported previously [42] [43] [44] , but identification of specific follistatindependent mechanisms involved will require further investigation.
In summary, the studies presented here, utilizing a combination of siRNA-mediated gene knockdown and pharmacological approaches, demonstrate that SMAD2 and SMAD3 are both key genes affecting bovine early embryogenesis. Moreover, we documented that specific embryotropic actions of follistatin in cattle are lost when SMAD2/3 signaling is ablated, further supporting our previous data showing specific embryotropic actions of follistatin are dependent on the common SMAD (SMAD4) linked to signaling via both SMAD2/3 and SMAD1/5/8 pathways. Further investigation of the mechanisms underlying the requirements of SMAD2/3/4 and follistatin in early embryogenesis will shed novel insights on understanding of regulation of early embryonic development and potential mechanisms contributing to infertility and success of ART in cattle and potentially in humans.
